Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era

Clinical Breast Cancer

Volumn 8, Issue 5, 2008, Pages 436-442

  Montemurro, Filippo ^a   Redana, Stefania ^a   Viale, Giuseppe ^b   Sanna, Giuseppina ^b   Donadio, Michela ^c   Valabrega, Giorgio ^a   Del Curto, Barbara ^b   Bottini, Alberto ^d   Botti, Gerardo ^e   Paolo Dei Tos, Angelo ^f   Jacomuzzi, Maria Elena ^g   Di Bonito, Maurizio ^e   Danese, Saverio ^h   Clavarezza, Matteo ⁱ   Kulka, Janina ^j   Di Palma, Silvana ^k   Durando, Antonio ^h   Sapino, Anna ^l   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Centro Oncologico Subalpino (COES)   (Italy)

^d CREMONA HOSPITAL   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f OSPEDALE CA FONCELLO   (Italy)

^g MAURIZIANO HOSPITAL   (Italy)

^h Ospedale S Anna   (Italy)

ⁱ Istituto Nazionale Tumori   (Italy)

^j SEMMELWEIS UNIVERSITY   (Hungary)

^k ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^l MOLINETTE HOSPITAL   (Italy)

more..

Author keywords

Breast neoplasms; Disease progression; Drug resistance; Tyrosine kinase inhibition

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HORMONAL THERAPY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD; ONCOGENE NEU; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; BREAST TUMOR; CLINICAL TRIAL; DISEASE COURSE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 58149235344     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.053     Document Type: Article

References (24)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
2. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-74.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-72.
4. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-84.
5. Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007; 7:257-68.
6. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-43.
7. Tan-Chiu E, Kaufman PA, Paik S, et al. registHER: a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer. J Clin Oncol 2005; 23:44s (Abstract 670).
8. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-51.
9. Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96:739-49.
10. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5:52-8.
11. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003; 4:120-5.
12. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22:1063-70.
13. Extra JM, Antoine EC, Vincent-Salomon A, et al. Favourable effect of continued trastuzumab treatment in metastatic breast cancer patients: results from the French Hermine cohort study. Breast Cancer Res Treat 2006; 100:S102 (Abstract 2064).
14. Pusztai L, Esteva FJ. Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest 2006; 24:187-91.
15. Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006; 11:318-24.
16. Hortobagyi GN. In Reply: Continuation of trastuzumab beyond disease progression. J Clin Oncol 2005; 23:2868-9.
17. von Minckwitz G, Vogel P, Schmidt M, et al. Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer -the TBP study (GBG 26/BIG 3-05). Breast Cancer Res Treat 2007; 106:S185 (Abstract 4056).
18. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
19. Montemurro F, Aglietta M. Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer? Nat Clin Pract Oncol 2007; 4:398-9.
20. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18:977-84.
21. Scaltriti M, Rojo F, Ocaãa A, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99:628-38.
22. Fumoleau P, Wardley A, Miles D, et al. Safety of pertuzumab plus trastuzumab in a Phase II trial of patients with HER2-overexpressing metastatic breast cancer which had progressed during trastuzumab therapy. Breast Cancer Res Treat 2007; 106:S19 (Abstract 73).
23. Modi S, Stopeck A, Kinden H, et al. Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): phase 2 trial. Breast Cancer Res Treat 2007; 106:S269 (Abstract 6066).
24. ALTTO Study [Web site]. Neo-ALTTO. Neo-adjuvant lapatinib and/or trastuzumab treatment optimisation trial. Available at: http://www.alttotrials.com/neoaltto. php